louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05453045: Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva
Official title: Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pharmacological Action
Lead sponsor: Universidad Nacional de Salta
Sponsor class: OTHER
Collaborators: name: Fundacion Mundo Sano
First posted: 2022-07-12
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This project will develop and assess the feasibility and acceptability of a salive-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the salive and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites.The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.


Eligibility criteria: Inclusion Criteria:

Body Mass Index: 18 to 25.

Physical exam without significant abnormal findings.

Exclusion Criteria:

Pregnancy

Lactation

Use of ABZ or other benzimidazole drugs in the previous 30 days

History of intolerance to ABZ

Malabsorption and/or other gastrointestinal conditions that might compromise ABZ absorption.

Primary outcomes:
measure: Salive albendazole levels
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01373645: Safety and Efficacy Registry of Yinyi Stent
Official title: Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Coronary Artery Disease
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2011-06-15
Enrollment: 1045
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Drug-eluting stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. Persistent polymer could be responsible. Local delivery of paclitxel from a polymer-free Yinyi stent (Dalian Yinyi biomaterial research and development co.ltd) may prevent these complications.


Eligibility criteria: Inclusion Criteria:

* age 18-80 years old
* both gender
* native coronary lesion
* narrowing \> 70%
* vessel size 2.5-4.0 in diameter

Exclusion Criteria:

* without informed consent,
* ST elevation myocardial infarction within 7 days,
* patient with ≤ 70% coronary narrowing at target lesion,
* left main lesion,
* multivessel narrowing need more than 3 stent implantations,
* by-pass graft,
* abnormal liver function before randomization,
* active hepatitis or muscular disease,
* impaired renal function with serum creatinine level \> 3mg/dl,
* impaired left ventricular function with LVEF \< 30%,
* Participate in other studies.

Primary outcomes:
measure: major adverse cardiac events
timeFrame: 12 months
Secondary outcomes:
measure: stent thrombosis
timeFrame: 12 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: ruijin hospital, Shanghai Jiao Tong University, School of Medicine
state: Shanghai
Study officials:
References:
citation: Zhang RY, Zhang Q, Zhu JZ, Chen LL, Zhang CY, Zhou XC, Yuan Y, Zhong ZX, Li L, Qiu J, Wang W, Chen XM, Yang ZJ, Yan JC, Chen SL, Hou YQ, Wu YQ, Luo HM, Qiu JP, Zhu L, Wang Y, Fu GS, Wang JA, Ma KH, Yin YH, Zhang DF, Hu XS, Zhu GY, Shen WF; Safety and Efficacy Registry of Yinyi stent (SERY-I) Investigators. Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry. Chin Med J (Engl). 2011 Nov;124(21):3521-6. No abstract available.
Clinical trial NCT01809145: Testing Hypersensitivity to Metals in Sarcoidosis Patients by Applying the MELISA Test.
Official title: Testing Hypersensitivity to Metals in Sarcoidosis Patients With Occupational Exposure, Using the MELISA Test.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sarcoidosis
Keywords: sarcoidosis
occupational exposure
MELISA
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2013-03-12
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to apply the MELISA test, that diagnose hypersensitivity to metals, in Sarcoidosis patients with occupational exposure.

Detailed description: Peripheral blood from sarcoidosis patients with occupational anamnesis that involves exposure to metals will be sent to MELISA Medica in Stockholm Sweden. The MELISA test will examine hypersensitivity to metals that can be related to the granulomatous response of sarcoidosis.

Eligibility criteria: Inclusion Criteria:

Biopsy confirmed sarcoidosis Granulomatous disease Occupational anamnesis with exposure to metals

Exclusion Criteria:

Patients with interstitial disease No occupational anamnesis

Primary outcomes:
measure: MELISA test
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel-Aviv Sourasky Medical Center
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Elizabeth Fireman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02698345: Korean Multicenter Prospective Registry of In.PACT DEB for Isolated Popliteal Artery Disease (K-POP Study)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Popliteal Artery Disease
Keywords: Popliteal artery disease, drug-eluting balloon, angioplasty
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2016-03-03
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with isolated popliteal artery disease

Brief summary: * Prospective, multi-center, single-arm registry study
* A total of 100 subjects with isolated popliteal artery lesions according to inclusion and exclusion criteria will be enrolled.
* All popliteal artery lesions will be treated with drug-eluting balloon (In.PACT Admiral, Medtronic). • Atherectomy or use of bare nitinol stent in combination with drug-eluting balloon is allowed • Patients will be followed clinically for 12 months after the procedure.
* Imaging study (Duplex ultrasound, CT angiography or catheter angiography) follow-up will be performed at 12 months.


Eligibility criteria: Inclusion Criteria:

1. Age 19 years or older
2. Symptomatic peripheral artery disease:

   * Moderate or severe claudication (Rutherford category 2 or 3)
   * Critical limb ischemia (Rutherford category 4 or 5)
3. Atherosclerotic popliteal artery disease (stenosis \> 50%)
4. Patients with signed informed consent

Exclusion Criteria:

1. Acute critical limb ischemia
2. Severe critical limb ischemia (Rutherford category 6)
3. Involvement of SFA disease with stenosis
4. Continous total occlusion of all proximal infrapopliteal arteries (origin of the anterior tibial artery or tibioperoneal trunk).
5. Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, or contrast agent
6. Age \> 85 years
7. Severe hepatic dysfunction (\> 3 times normal reference values)
8. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
9. LVEF \< 40% or clinically overt congestive heart failure
10. Pregnant women or women with potential childbearing
11. Life expectancy \<1 year due to comorbidity
12. Previous bypass surgery or stenting for the target popliteal artery
13. Untreated inflow disease of the ipsilateral pelvic or femoropopliteal arteries (more than 50% stenosis or occlusion)

Primary outcomes:
measure: Primary patency rate
timeFrame: 12 months after the index procedure
Secondary outcomes:
measure: Target vessel revascularization rate
timeFrame: 12 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
Clinical trial NCT02855645: The Effects of Trichosanthes Root on Blood Sugar in Patients With Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Diabetes Mellitus
Keywords: Trichosanthes root
Traditional Chinese Medicine
Clinical trial
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2016-08-04
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Diabetes mellitus (DM) locates fifth of ten leading death etiology, the population of diabetic patients has a tendency of increase. Trichosanthes root is called as Tian Hua Fen, According to traditional Chinese writing record that Trichosanthes root has the action of downbear fire, moisten dryness, and slippery phlegm, and release thirst. The Trichosanthes root may lower blood sugar levels in the modern study. The investigators designed a double blind, randomized controlled study, a total of 60 diabetic patients with high blood sugar were divided into treatment and control groups, and each group was 30 patients. In the treatment group, oral administration of Trichosanthes root 1.5 g, bid/day for 84 days continuously; in the control group, oral administration of Trichosanthes root placebo 1.5 g, bid/day for 84 days continuously. The main outcome measure was the changes of plasma blood sugar and Glycated hemoglobin A1c (HbA1c) levels changed before and after Trichosanthes root treatment. The investigators predict the results of the present study indicated that Trichosanthes root can improve plasma blood sugar and glycated hemoglobin A1c levels.


Eligibility criteria: Inclusion Criteria:

1. Early diagnosis Type Ⅱ Diabetic patients who Glycated hemoglobin A1c level between 7.0% and 9.0% (including) , and after three months of diet and exercise control.
2. The subject who was taking hypoglycemic drugs Metformin, the maximum total amount of ≦ 1500 mg / day.
3. Age ranged between 20 and 80 years (including).

Exclusion Criteria:

1. Pregnancy or breast-finding.
2. Allergy to test medicine.
3. Type I Diabetic patients.
4. Bleeding tendency.
5. The participants who suffered from serious disorders, such as congestive heart failure, myocardial infarction, chronic obstructive pulmonary disease, renal failure, cancer or stroke etc.
6. Irritable or anxious patients who cannot be assessed.
7. Refuse to sign the agreement.
8. The values of SGOT and SGPT levels were more than normal limit triple, or the value of creatinine level was more than normal limit.
9. Plasm glucose(Glucose AC) level in fasting state ≧ 300 mg / dL.

Primary outcomes:
measure: Glycated hemoglobin A1c
timeFrame: Three months
measure: Plasma Blood Sugar
timeFrame: Three months
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
Study officials:
affiliation: China Medical University Hospital
name: Ching-Liang Hsieh
role: STUDY_CHAIR
References:
Clinical trial NCT04916145: An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults
Official title: A Single-center, Randomized, Open Label, No-treatment Controlled, Digital Device Study to Evaluate the Efficacy, Safety and Feasibility of SAT-008 in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Allergy and Immunology
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
Collaborators: name: Korea University Guro Hospital
name: S-Alpha Therapeutics, Inc.
First posted: 2021-06-07
Enrollment: 42
Sex: ALL
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to one of two study arms. One group (treatment) will receive an experimental digital device for 13 weeks while the other group (control) will maintain daily activity as usual.
Primary purpose: PREVENTION

Brief summary: The purpose of this exploratory study is to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-008 in healthy adults.

Detailed description: This clinical study was designed as a single institution, open, controlled, and investigator-led clinical trial to evaluate the efficacy, safety, and feasibility of a novel digital device called SAT-008 in healthy adults.

Eligibility criteria: Inclusion Criteria:

* Healthy adults aged 19 to 50 years
* Received influenza vaccination the previous year
* Scheduled to receive the influenza vaccine
* Voluntarily agrees with a consent form

Exclusion Criteria:

* Current infectious disease
* History of autoimmune diseases
* Current immunological compromised diseases.

Primary outcomes:
measure: Changes in functions of immunocytes
timeFrame: Baseline, Week 1, Week 5, Week 13
measure: Number of expected and unexpected adverse events
timeFrame: Baseline
measure: Number of expected and unexpected adverse events
timeFrame: Week 1 (a week following baseline)
measure: Number of expected and unexpected adverse events
timeFrame: Week 5 (five weeks following baseline)
measure: Number of expected and unexpected adverse events
timeFrame: Week 13 (thirteen weeks following baseline)
measure: Rate of adherence to SAT-008
timeFrame: Week 1 (a week following baseline)
measure: Rate of adherence to SAT-008
timeFrame: Week 5 (five weeks following baseline)
measure: Rate of adherence to SAT-008
timeFrame: Week 13 (thirteen weeks following baseline)
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: addchang@snu.ac.kr
name: Yoon-Seok Chang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00479245: WHODAS-II for Patients With Nonspecific Low Back Pain
Official title: WHODAS-II for Patients With Nonspecific Low Back Pain
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Low Back Pain
Keywords: nonspecific low back pain
disability
fear avoidance beliefs
quality of life
Lead sponsor: Kovacs Foundation
Sponsor class: OTHER
First posted: 2007-05-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The main purpose of this study is to determine the measurement characteristics of WHODAS-II (World Health Organization Disability Assessment Schedule), as well as to analyze its correlation with low back pain (Visual Analog Scale, VAS), disability (Spanish version of the Roland Morris Questionnaire, RMQ), fear avoidance beliefs and attitudes (Spanish version of the FAB Questionnaire, FABQ) and quality of life (SF-12). Measurements will be taken at baseline and 6 days later (day 7).


Eligibility criteria: Inclusion Criteria:

* Patients seen for nonspecific low back pain, with or without referred pain
* Able to read and write
* Have signed the informed consent form

Exclusion Criteria:

* Central nervous system pathology (with or without treatment)
* Diagnosis of rheumatic inflammatory disease or fibromyalgia
* Red flags for underlying systemic disease
* Criteria for diagnosis of symptomatic herniated disc or symptomatic spinal stenosis

Primary outcomes:
measure: Measurement characteristics of WHODAS-II
timeFrame: At baseline and at 7 days
Secondary outcomes:
measure: Correlation between WHODAS-II and VAS, RMQ, FABQ and SF-12 in nonspecific low back pain
timeFrame: At baseline and at 7 days
Other outcomes:
Locations:
city: Santander
country: Spain
facility: Hospital Universitario Marqués de Valdecilla
state: Cantabria
Study officials:
affiliation: Kovacs Foundation, Palma de Mallorca, Spain
name: Francisco M Kovacs, MD, PhD
role: STUDY_DIRECTOR
affiliation: Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
name: José Luis Peña, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders. Introduction. Spine (Phila Pa 1976). 2000 Dec 15;25(24):3097-9. doi: 10.1097/00007632-200012150-00002. No abstract available.
citation: Chwastiak LA, Von Korff M. Disability in depression and back pain: evaluation of the World Health Organization Disability Assessment Schedule (WHO DAS II) in a primary care setting. J Clin Epidemiol. 2003 Jun;56(6):507-14. doi: 10.1016/s0895-4356(03)00051-9.
citation: van Tubergen A, Landewe R, Heuft-Dorenbosch L, Spoorenberg A, van der Heijde D, van der Tempel H, van der Linden S. Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Feb;62(2):140-5. doi: 10.1136/ard.62.2.140.
Clinical trial NCT00276445: Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan
Official title: Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Allergic Conjunctivitis
Keywords: allergy
Allergy conjunctivitis
beta-1-3glucan
Th1/Th2
Lead sponsor: Meiji University of Oriental Medicine
Sponsor class: OTHER
Collaborators: name: Kyoto Prefectural University of Medicine
First posted: 2006-01-13
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Intravenous- injection of beta-1,3-glucan in human is known to induce T helper type 1 response, while oral uptake did not. It was examined whether superfine dispersed beta-1,3-glucan (SDG) contrived to absorbed by intestinal mucosa would alleviate allergic symptoms by per-oral ingestion

Detailed description: Beta-1,3-glucan made from Japanese mushroom is commercially available for healthy foodstuffs. Allergy patients were orally administrated either SDG (n=30) or non-dispersed beta-1,3-glucan (NDG, n=30) and allergic symptoms were assessed clinically, by the double-blind, placebo-controlled, randomized study

Eligibility criteria: Inclusion Criteria:

* history of seasonal allergic conjunctivitis with or without rhinitis in spring (Japanese cedar pollen season) every year
* positive allergen specific IgE (\> 30 IU/ml) or positive skin prick test result (wheal diameter \> 3mm) to Japanese cedar, Orchard Grass pollen, or house dust-mite extract

Exclusion Criteria:

* Patients who had undergone immunotherapy in the previous 5 years
* a history of other immunological or medically relevant diseases

Primary outcomes:
measure: Symptoms were assessed clinically by score on a allergic symptom rating scale.
Secondary outcomes:
measure: Total IgE and allergen specific IgE were measured.
measure: The binding capacity of beta-1,3-glucan to peripheral CD14+ cells were assessed.
Other outcomes:
Locations:
city: Kyoto
country: Japan
facility: Meiji University of Oriental Medicine
Study officials:
affiliation: Meiji University of Oriental Medicine
name: Jun Yamada, M.D. Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Kyoto Prefectural University of Medicine
name: Junji Hamuro, Ph.D.
role: STUDY_DIRECTOR
affiliation: Kyoto Prefectural University of Medicine
name: Shigeru Kinoshita, M.D. Ph.D.
role: STUDY_CHAIR
References:
citation: Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature. 1969 May 17;222(5194):687-8. doi: 10.1038/222687a0. No abstract available.
Clinical trial NCT00741845: Prevention of Persistence of Bacterial Vaginosis
Official title: Prevention of Persistence of Bacterial Vaginosis: The Effects of High Dose Intravaginal Metronidazole
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Bacterial Vaginosis
Lead sponsor: Embil Pharmaceutical Co. Ltd
Sponsor class: INDUSTRY
First posted: 2008-08-26
Enrollment: 117
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This purpose of this study will be to conduct a double-blind, randomized, controlled clinical trial to determine the association between intravaginal high dose metronidazole (750mg), intravaginal high dose metronidazole combined with an antifungal agent(750mg metronidazole + 200mg miconazole) and low dose (37.5mg) intravaginal metronidazole, with the rate of persistent bacterial vaginosis.


Eligibility criteria: Inclusion Criteria:

* women 18-40 yrs old
* abnormal vaginal discharge or malodor
* positive QuickVue test
* positive KOH whiff test
* Positive finding of clue cells greater than or equal to 20% on wet mount
* Able to give informed consent
* willing to abstain from alcohol during the 5 day therapy and 1 day following

Exclusion Criteria:

* immunocompromised women
* symptomatic VVC
* pregnancy or positive pregnancy test
* menstruating or breastfeeding women
* other oral or vaginal antifungal or antimicrobial drugs w/in past 2 wks
* women with MPC, PID

Primary outcomes:
measure: The specific aim of this study is to compare the rate of persistence of BV in non-pregnant women randomized to one of three different schemes of intravaginal metronidazole given nightly for 5 nights
timeFrame: 28 days after therapy initiation
Secondary outcomes:
Other outcomes:
Locations:
city: Lima
country: Peru
facility: Cayetano Heredia Hospital
state: Urb Ingenieria
Study officials:
References:
Clinical trial NCT00000345: Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10
Official title: Evaluation of Lofexidine for Treatment of Opiate Withdrawal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Opioid-Related Disorders
Keywords: opioid dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety of lofexidine in the treatment of opiate-dependent individuals.


Eligibility criteria: Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Primary outcomes:
measure: Opiate withdrawal
measure: Adverse effect measures
measure: Craving of opiates
measure: Liking of opiates
measure: Efficacy of lofexidine
measure: Euphoria
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Friends Research Institute
state: California
Study officials:
affiliation: Friends Research Institute, Inc.
name: Walter Ling, M.D.
role: PRINCIPAL_INVESTIGATOR
References: